Login to Your Account

Amgen overcomes CRL to win U.S. approval for Parsabiv

By Michael Fitzhugh
Staff Writer

Wednesday, February 8, 2017

Six months later than first expected, FDA approval for Amgen Inc.'s secondary hyperparathyroidism (SHPT) treatment, Parsabiv (etelcalcetide), has arrived.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription